Literature DB >> 16402954

Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by sequential gas displacement and photodynamic therapy: a pilot study of one-year follow up.

Wai-Man Chan1, David T L Liu, Timothy Y Y Lai, Haitao Li, Jian-Ping Tong, Dennis S C Lam.   

Abstract

BACKGROUND: Polypoidal choroidal vasculopathy (PCV) with peculiar vascular lesions presents frequently as recurrent submacular haemorrhage. The best treatment is still not certain. It is the authors' objective to evaluate the 1-year safety and efficacy of photodynamic therapy (PDT) using verteporfin for persistent macular PCV after pneumatic displacement of the massive submacular haemorrhage with intravitreal perfluoropropane (C(3)F(8)).
METHODS: A prospective, non-comparative, interventional case series on patients with extensive and thick submacular haemorrhage secondary to PCV, which was displaced pneumatically with intravitreal pure 0.4 ml C(3)F(8). Fluorescein angiography and indocyanine green angiography were repeated 1-2 weeks later to delineate any persistent active leaking polypoidal lesions, which were then treated with PDT. Retreatment might be considered in each follow up at every 3 months.
RESULTS: Six eyes of six patients with the mean age of 53.6 years had been recruited and completed 1-year follow up. The mean baseline Snellen equivalent best-corrected visual acuity (BCVA) was 6/92 and the mean final BCVA at 1 year was 6/17. The mean improvement in logMAR BCVA after the sequential treatments was seven lines (range +3 to +19 lines) (Wilcoxon signed-ranks test, P = 0.03). All patients had at least moderate visual gains. No patient suffered serious complications from PDT.
CONCLUSIONS: This first report on combined treatment with intravitreal gas injection and sequential PDT on PCV seems to be a well-tolerated option. Further comparative studies with larger sample size and longer follow up are warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16402954     DOI: 10.1111/j.1442-9071.2005.01105.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  10 in total

1.  Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Chengguo Zuo; Feng Wen; Jiaqing Li; Yan Liu; Meng Li
Journal:  Doc Ophthalmol       Date:  2009-01-31       Impact factor: 2.379

2.  Six-month visual prognosis in eyes with submacular hemorrhage secondary to age-related macular degeneration or polypoidal choroidal vasculopathy.

Authors:  Chui Ming Gemmy Cheung; Mayuri Bhargava; Li Xiang; Ranjana Mathur; Chan Choi Mun; Doric Wong; Tien Yin Wong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-26       Impact factor: 3.117

3.  Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients.

Authors:  Suk Ho Byeon; Sung Chul Lee; Hyun-Sub Oh; Sung Soo Kim; Hyoung Jun Koh; Oh Woong Kwon
Journal:  Jpn J Ophthalmol       Date:  2008-03-28       Impact factor: 2.447

Review 4.  Verteporfin PDT for non-standard indications--a review of current literature.

Authors:  Wai Man Chan; Tock-Han Lim; Alfredo Pece; Rufino Silva; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-17       Impact factor: 3.117

Review 5.  Polypoidal choroidal vasculopathy: An update on current management and review of literature.

Authors:  Amit Harishchandra Palkar; Vikas Khetan
Journal:  Taiwan J Ophthalmol       Date:  2019 Apr-Jun

6.  Polypoidal Choroidal Vasculopathy.

Authors:  Joon-Bom Kim; Rajinder S Nirwan; Ajay E Kuriyan
Journal:  Curr Ophthalmol Rep       Date:  2017-04-21

7.  The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy.

Authors:  Sun Young Lee; June Gone Kim; Soo Geun Joe; Hyewon Chung; Young Hee Yoon
Journal:  Korean J Ophthalmol       Date:  2008-06

Review 8.  Polypoidal choroidal vasculopathy: an update on therapeutic approaches.

Authors:  Raymond L M Wong; Timothy Y Y Lai
Journal:  J Ophthalmic Vis Res       Date:  2013-10

9.  Pneumatic displacement with intravitreal bevacizumab for massive submacular hemorrhage due to polypoidal choroidal vasculopathy.

Authors:  Masayasu Kitahashi; Takayuki Baba; Madoka Sakurai; Hirotaka Yokouchi; Mariko Kubota-Taniai; Yoshinori Mitamura; Shuichi Yamamoto
Journal:  Clin Ophthalmol       Date:  2014-03-03

10.  23-Gauge vitrectomy with external drainage therapy as a novel procedure to displace massive submacular hemorrhage secondary to polypoidal choroidal vasculopathy.

Authors:  Hui Liu; Lu-Yi Zhang; Xiao-Xia Li; Miao-Qin Wu
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.